Latest news with #Varian
Zawya
23-07-2025
- Business
- Zawya
Alameda Healthcare Group to install second linear accelerator system at Dar Al-Fouad Hospital
Cairo, Alameda Healthcare Group, a leading healthcare provider in Egypt, is proud to announce the installation of a second state-of-the-art Linear Accelerator System (LINAC) at Dar Al-Fouad Hospital – 6th of October, reinforcing its strategic alliance with Siemens Healthineers, a global leader in medical technology, and Varian, acquired by Siemens Healthineers, to advance Radiation Therapy Services in Egypt. The new TrueBeam system, scheduled for installation before the end of 2025, represents a significant milestone in Alameda's ongoing commitment to expanding access to high-precision oncology treatments. As part of the Group's broader strategy to elevate cancer care, the TrueBeam system will enable the treatment of both highly specialized and conformal cases, offering enhanced speed, accuracy, and patient comfort. This development is part of a strategic agreement between Alameda, Siemens Healthineers, and Varian, a part of Siemens Healthineers' portfolio of solutions, aimed at transforming the oncology care ecosystem in Egypt through the adoption of advanced technologies and global best practices. Dr. Fahad Khater, Chairman of Alameda Healthcare Group, commented, 'This installation marks an important step in our mission to offer world-class oncology services that are highly accessible. With the addition of a second LINAC system at our 6th of October facility, we are significantly boosting our treatment capacity and furthering our vision to provide cutting-edge, compassionate care to every patient.' Amro Kandil, CEO and Managing Director of Siemens Healthineers Egypt, added, 'At Siemens Healthineers, we are proud to support Alameda in its mission to provide top-notch oncology care in Egypt. The integration of the TrueBeam system at Dar Al-Fouad Hospital exemplifies the impact of strategic collaboration in improving patient outcomes. Through this ongoing partnership, we continue to enable access to advanced, precise, and patient-centered radiotherapy technologies.' The TrueBeam system is renowned for its versatility and precision in delivering image-guided radiotherapy and radiosurgery. This expansion also reflects the Group's ongoing investment in advanced medical infrastructure and its commitment to meeting the increasing needs of cancer patients across Egypt.
Business Wire
15-07-2025
- Business
- Business Wire
Varian Introduces IntelliBlate in Europe, Advancing an Integrated Microwave Ablation Solution for Image-Guided Cancer Therapy
PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, today announced the European launch of IntelliBlate, its next generation microwave ablation solution, for the treatment of soft tissue tumors. Now CE-marked, IntelliBlate represents a pivotal milestone in expanding access to an integrated, intuitive, and minimally invasive treatment option for clinicians and patients across Europe. Designed to provide clinicians with greater predictability, precision, and control, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation. This therapeutic device complements the Siemens Healthineers' suite of imaging and software solutions including: myAblation Guide for planning and post-procedural confirmation software, myNeedle Laser guidance system that enhances placement with a CT scan, and ultrasound for assessment, placement, and monitoring during treatment. With the addition of IntelliBlate, the Varian and Siemens Healthineers' offerings allow clinicians to plan, place, treat, monitor, and confirm ablation therapy in one environment, simplifying workflow and supporting greater confidence in targeting and treatment. IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. It produces large, controlled spherical ablation zones for predictable treatment delivery. A novel feature, the Ximitry probe's thermocouples provide continuous temperature monitoring inside and outside the ablation zone, allowing clinicians to observe real-time temperature changes and make informed decisions. The system provides two generators in one system making it compact and portable. The intuitive interface with fast set up and pre-programmed ablation zone settings makes the IntelliBlate a streamlined solution that helps reduce procedural barriers. Following receipt of its U.S. FDA market clearance in 2024, IntelliBlate enters the European market at a time of growing clinical evidence around thermal ablation. The COLLISION trial 1, a large international phase 3 study, published in The Lancet Oncology, demonstrated that thermal ablation can be as effective as the gold standard, surgical resection alone, in treating small-size colorectal liver metastases (CRLM) while resulting in significantly fewer complications, comparable overall survival, and shorter hospital stays for patients. 'The results of the COLLISION trial mark a milestone in how we think about ablation,' said Franck Facchini, President of Interventional Solutions at Varian. 'We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery. IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.' IntelliBlate will be introduced to the European clinical community in September at CIRSE 2025, the leading European Congress for interventional radiology in which Varian and Siemens Healthineers will offer hands-on demonstrations and educational sessions to support training, best practice and early clinical adoption. IntelliBlate represents a more targeted, less invasive approach to cancer care, offering new options to clinicians and new hope to patients. It reflects Varian's commitment and investment to becoming a leading innovator in interventional solutions and envisioning a world without the fear of cancer. Varian's journey with Siemens Healthineers is just getting started; together, we are committed to the continued development of a smart, integrated approach that connects innovative therapy technologies and image-guided solutions. © 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners. About Varian At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit QR700024726
Business Wire
26-06-2025
- Business
- Business Wire
Icon Group and Varian Expand Global Partnership to Deliver Advanced Cancer Technology Across the UK
LONDON--(BUSINESS WIRE)--Icon Group, a global leader in integrated cancer care, has announced a significant new agreement with Varian, a Siemens Healthineers company, involving an investment of more than USD $18.7 million to expand access to cutting-edge, world-class cancer treatment technology across the United Kingdom. The agreement includes the rollout of Varian's advanced TrueBeam linear accelerators, along with next-generation imaging and software platforms such as RapidArc Dynamic (RAD), HyperSight, IDENTIFY, and a continued pipeline of new technology, designed to deliver faster, highly precise, patient-centred care. This investment reinforces Icon's ongoing commitment to increasing access to world-class, precision-led cancer care and marks the first installation of this full suite of comprehensive Varian hardware and software in the UK. The technology will be rolled out across Icon Cancer Centre London and three new locations in Brighton, Warwickshire, and Derby, with further installations planned to support Icon's growing footprint in the region. Icon Europe CEO, Aldo Rolfo said this technology will increase access to world-class care. 'At Icon, we're market leaders in introducing the absolute latest in radiotherapy technologies and treatments and ensuring we increase access to world-class care to communities we serve,' said Aldo. 'This large investment with Varian enables us to continue leading in precision cancer care and improving access to treatment and better outcomes for patients across the UK.' Enhancing patient experience and outcomes The new agreement will introduce Varian's most innovative technologies to UK patients, delivering faster treatment times, more precise imaging and delivery, and streamlined workflows that aim to improve the overall treatment experience: TrueBeam – an advanced linear accelerator (radiation therapy treatment machine) designed to deliver high-speed, image-guided radiation therapy for a wide range of cancers. RapidArc Dynamic (RAD) – a state-of-the-art planning and delivery platform that reduces treatment planning time by up to 70% while enhancing plan quality and reducing dose exposure to critical organs. HyperSight – advanced cone-beam CT imaging delivering clearer, faster images, that enhance anatomical visualisation and support more precise treatment delivery, while also helping streamline workflows by reducing image acquisition time. IDENTIFY – real-time surface-guided radiotherapy (SGRT) that increases treatment accuracy and can significantly reduce, and in many cases eliminate, the need for permanents tattoo markings, a sometime unfriendly reminder of a patient's diagnosis. The first installations will take place at Icon Cancer Centre London, with other sites following later in 2026. Icon Group's UK Chief Medical Officer, Dr Penny Kechagioglou said this new technology is a game-changer. 'This technology marks a new benchmark for radiotherapy in the UK,' said Dr Kechagioglou. 'There is currently an underutilisation of radiotherapy treatment, with fewer than 30% of cancer patients receiving it, less than the global recommended rate of 40 – 50% of cancer diagnosis 1. 'This is a real win for cancer patients who will benefit from timely access to highly advanced non-invasive radiotherapy designed to improve both patient experience and outcomes.' Head of Varian Europe, Middle East and Africa, Virve Sarja is looking forward to rolling out this technology. 'We're proud to strengthen our collaboration with Icon in the UK,' said Virve. 'This partnership reflects a shared commitment to expanding access to cutting edge radiotherapy technologies in the region and redefining what's possible in cancer treatment. By combining innovation with a strong focus on patient care, we're helping to raise the standard of treatment and move closer to a world without fear of cancer.' © 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners. References 1 Cancer Research UK About Icon Group Icon Group is a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom. Icon is built on a strong but simple mission - to deliver the best care possible to as many people as possible, as close to home as possible. The group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, theranostics, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With more than 3,500 team members, a network of more than 350 doctors, over 55 cancer centres, six compounding facilities and operational support of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden. For more information visit and follow Icon Group on LinkedIn at About Varian At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit Icon and Varian's global partnership Icon Group and Varian have a long history of collaboration in delivering advanced cancer care across Australia, New Zealand, Asia, and now the UK. Icon clinicians and medical professionals are active members of Varian's global AI and RapidArc Dynamic consortiums and are engaged in clinical research and product development initiatives worldwide. The expanded partnership in the UK also builds on a five-year professional services and research agreement between Icon and Varian established in 2022 and highlights a shared commitment to innovation, access, and improved patient outcomes. QR700024577
Powys County Times
17-06-2025
- Sport
- Powys County Times
Fallen Angel aiming to get back on right path in Cambridge
Fallen Angel is expected to take a big leap forward from her comeback run in the Lockinge when she returns to fillies-only company in the Duke of Cambridge Stakes on Wednesday. The Too Darn Hot filly was sixth of eight runners at Newbury as a route towards the Royal meeting was plotted by trainer Karl Burke. Richard Brown, racing adviser to owners Wathnan Racing, believes the four-year-old will benefit from that outing and said: 'This has been the plan for a long time with her and she ran a very nice comeback race in the Lockinge, so we were delighted with that. 'We don't really think she is a spring filly and Karl says she just takes time to come to herself, she is not a great work filly at home so it can be hard to judge her. But he seems very happy with her now. 'Her last piece of work was good and she has come fully in her coat now, which wasn't the case at Newbury, and last year we saw she got beat in the English Guineas before bouncing back to win in Ireland. 'I think she will definitely have improved for the run and she is a gorgeous filly who we can't wait to see run.' Wathnan also own the John and Thady Gosden-trained Crimson Advocate who has improved since stepping up in trip and Brown said: 'She will also go and won the Queen Mary at the meeting two years ago. She's been very good and consistent since stepped up to a mile and I'm sure she will run an admirable race as well, she never lets us down.' Elmalka was second behind Cinderella's Dream in the Dahlia Stakes at Newmarket last month and trainer Roger Varian will drop her back in trip having taken in the Prix d'Ispahan last time out. Varian told Sky Sports Racing: 'I thought she ran really well in the Dahlia Stakes, it was a good renewal. I then ran her in the d'Ispahan against the colts and in hindsight maybe that was the wrong thing to do but the winner (Sosie) was supplemented at the last minute, none of us had an idea he'd be running. 'She wasn't quite good enough against strong colts but she still ran well and it made my mind up that she's a miler, so we're taking the positives. 'It will be quite tough to turn the form around with Cinderella's Dream as she was impressive that day but Elmalka is a good filly in her own right.' Varian has had to bide his time with My Cloud but is confident he can take another step forward in the Royal Hunt Cup. He said: 'He's a lovely horse, he's always been a nice horse but he's been late-developing, so we've had to be patient. He's won some nice races this year, in fairness it probably wasn't much of a race at Ascot that he won but he did well to win at Newbury on Lockinge day.' Michael Bell will be double handed with Greek Order and Tony Montana and believes both horses can give a good account of themselves. Bell said: 'Greek Order is an interesting horse having just come over from America. 'He looks as if he is on a very competitive mark and I think the draw (30) looks all right given that the principles in the betting are drawn next to him. 'Tony Montana is a very, very consistent, likeable horse.' Paddy Twomey's Carmers will put his unbeaten record on the line as he steps up to Group Two company in the Queen's Vase. Twomey said: 'Carmers is a nice horse, he made his debut at the start of May and he won nicely at Ballinrobe and stepped up markedly a week later in the Listed Yeats Stakes at Navan. 'We've had this race in mind for a while. I don't think any of the other horses in the race have won at a mile and six and I think he will handle the trip.' Old Is Gold impressed in winning at Beverley for Andrew Balding before being acquired by Wathnan and Brown is not worried about the step up in grade in the Windsor Castle Stakes. He said: 'I liked his run at Ascot and I like that he has course form. 'He was then impressive at Beverley and of course with our Naval Light (runs in the Norfolk), who we hold in high regard in second, it made sense to take that run very seriously.'
Tokyo Weekender
26-05-2025
- Health
- Tokyo Weekender
The Central Japan International Medical Center Is Revolutionizing Cancer Care
Nestled in the heart of Japan , the brand-new Central Japan International Medical Center (CJIMC) stands as a beacon of excellence in global health care. With state-of-the-art facilities and highly advanced technology, coupled with an intense focus on quality of care, CJIMC is emerging as a premier destination for international patients seeking top-tier medical services in Asia. 'Having seen medical care from all over the world, I designed this medical center with a global approach, equipped to treat patients from all backgrounds. The facility is supposed to feel more like a hotel than a hospital,' explains Dr. Jitsuhiro Yamada, the chairperson of Central Japan International Medical Center and a past international president of Lions Clubs International. CJIMC caters to patients of all backgrounds and nationalities — among them, medical tourists who come to Japan specifically to access cutting-edge care at a comparatively low cost. The facility offers a wide variety of services, including comprehensive health screenings and checkups, but what perhaps stands out most is its Proton Therapy Center, which is home to one of the world's most advanced and innovative radiation oncology treatment systems. Varian ProBeam 360° Revolutionizing Cancer Care At the heart of CJIMC's Proton Therapy Center lies the Varian ProBeam 360°, a highly advanced proton therapy system made in the US . Unlike traditional radiation therapy (which uses X-ray and gamma ray particles), the ProBeam 360° uses a proton particle beam, which is able to accurately zero in on tumors; this allows for unparalleled precision in targeting cancerous cells while minimizing damage to surrounding healthy tissues, proving particularly effective for treating cancers in delicate locations. 'Cancer is the scariest diagnosis a patient can receive,' Dr. Yamada says. 'We've integrated the ProBeam 360°, a highly effective, third-generation proton therapy equipment.' This cutting-edge treatment is offered in very few locations worldwide. 'We're working hard to make it easier for international patients to receive cutting-edge cancer treatment here.' Dr. Jitsuhiro Yamada The Proton Therapy Center is led by Dr. Nobukazu Fuwa, one of Japan's most respected radiation oncology experts, and treatments are delivered on an outpatient basis. Each treatment session usually takes 10 to 15 minutes, meaning that patients spend just a fraction of their day in the hospital. Though it varies based on cancer type and severity, Dr. Yamada says that proton therapy can sometimes conclude in around 21 sessions — for example, in the case of prostate cancer — allowing patients to receive a full course of treatment in a single month. It's an especially appealing option given the high costs of healthcare in America. 'With proton therapy that uses the American-made Varian system, even after purchasing round-trip airfare to Japan and getting gifts for your family here, the total cost would still be lower than just receiving treatment in the US,' notes Dr. Yamada. Elmammo PET scanner A Leading Force in Preventive Medicine Beyond specialized treatment, CJIMC is also a hub for preventive care and comprehensive health screening. The hospital offers full-body checkup packages designed to detect health issues at their earliest, most treatable stages — including full-body cancer screenings, cardiovascular system screenings and brain screenings. As such, it's an ideal destination for health-conscious travelers seeking peace of mind. The full-body cancer screening course includes an MRI, blood testing and a PET/CT scan, a combined imaging test that shows both the metabolic activity and detailed anatomy of one's body. In America, PET scans can cost several thousand dollars, and insurance can refuse to cover the examination if it's deemed not medically necessary. CJIMC is also equipped with an Elmammo PET scanner, a PET imaging system dedicated exclusively to breast cancer detection. This groundbreaking technology delivers highly accurate results without the discomfort of traditional mammography, making it an extremely popular option for female patients. International Support and Accessibility Recognizing the increasing demand from international patients, CJIMC works with English-speaking coordinators to assist with every step, from scheduling and payment to medical interpretation and aftercare support. Patient privacy and comfort are a top priority, and the facility's staff work hard to ensure that every international visitor experiences seamless, compassionate and culturally sensitive care. Although some overseas visitors may not be familiar with Gifu, it's centrally located and easy to reach from any of Japan's major cities. Situated just over an hour from Chubu Centrair International Airport and within easy reach of Nagoya, the hospital is easily accessible by high-speed rail, expressway or plane. Moreover, Gifu's beautiful nature and rich cultural heritage offer a peaceful and restorative environment — ideal for recovery and rehabilitation. Patients can experience the tranquility of Japan's heartland while receiving world-class medical care. Inuyama Inuyama Culture, History and Natural Beauty The medical center is located in close proximity to a number of scenic and culturally rich locations, which patients can explore once their treatment has concluded. Among them is the picturesque mountain village of Shirakawa-go, a UNESCO World Heritage Site famed for its traditional gassho-zukuri thatched-roof farmhouses — an enchanting, fairy tale-esque view. Nearby, the Okuhida region beckons with its dramatic 3,000-meter-class peaks and a wealth of natural hot springs, perfect for relaxation and recovery. Access is convenient: It takes just about 1 hour and 40 minutes by express train from the medical center to Takayama Station, which serves as the gateway to all these areas. The town of Inuyama, which neighbors CJIMC, is also full of things to do. It's home to Inuyama Castle, one of the five national treasure castles in Japan alongside Himeji and Matsumoto castles. Its main keep offers panoramic views of the Kiso River. The area surrounding the castle retains its Edo-period charm, with narrow lanes lined with traditional merchant houses, quaint shops and local eateries. The castle town is domestically known for the Inuyama Festival in early April, where intricately decorated floats are paraded through the streets, illuminated by hundreds of lanterns. Museum Meiji-Mura Museum Meiji-Mura Just a short distance from the castle, Museum Meiji-Mura is an open-air museum showcasing over 60 culturally significant buildings from the Meiji era. Among its treasures is the reconstructed main entrance of Tokyo's old Imperial Hotel, designed by Frank Lloyd Wright. Visitors can explore historic structures, ride a steam locomotive and wander through all 100 hectares of the whimsical park-museum steeped in nostalgia and historical significance. Elevating Global Health Standards As the world becomes more interconnected, the need for trusted, globally accessible health care providers continues to grow. With its fusion of cutting-edge technology, medical expertise and patient-centered care, Central Japan International Medical Center is poised to become a global leader in modern medicine. Whether it's the quiet dignity of individualized care or the seamless integration of some of the world's most advanced medical innovations, CJIMC embodies the values that have long placed Japan at the forefront of health care globally. 'I always teach new doctors that the center of medicine is not the doctor, but the patient. Patients come to us troubled by illness, and it is our job as doctors to use our knowledge to support them,' says Dr. Yamada. More Info Central Japan International Medical Center 1-1 Kenkonomachi, Minokamo, Gifu 505-8510 T: +81 574-66-1100
